<DOC>
	<DOCNO>NCT01662973</DOCNO>
	<brief_summary>Primary biliary cirrhosis ( PBC ) slowly progressive disease cause substantial loss intrahepatic bile duct , ultimately result cholestasis , advanced fibrosis , cirrhosis , liver failure even hepatocellular carcinoma . Histologically , disease characterize chronic portal inflammation infiltration , destruction loss epithelial cell small-sized medium-sized bile duct . Currently , Ursodeoxycholic acid ( UDCA ) dose 13-15mg/kg/day recommended therapeutic drug PBC AASLD approve indication U.S. Food Drug Administration ( FDA ) . Treatment UDCA may delay disease progression prolong survival free liver transplantation . However , one three patient adequately respond UDCA therapy many need additional medical therapy liver transplantation , . UC-MSC application treatment several severe autoimmune disease , immune thrombocytopenia , systemic lupus erythematosus , therapy-resistant rheumatoid arthritis . In study , safety efficacy UC-MSC transplantation PBC patient evaluate .</brief_summary>
	<brief_title>Umbilical Cord Mesenchymal Stem Cells Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description>Primary biliary cirrhosis ( PBC ) slowly progressive cholestatic disease associate development cirrhosis liver failure may justify liver transplantation . Ursodeoxycholic acid ( UDCA ) currently drug approve specifically treatment PBC . However , one three patient adequately respond UDCA therapy many need additional medical therapy liver transplantation , . The potential stem cell differentiate biliary epithelial cell recently confirm . In particular , bone marrow-derived mesenchymal stem cell ( BM-MSC ) transplantation applicated clinic treat several human disease GVHD , cardiac injury brain injury , display good tolerance efficiency . Recently , umbilical cord-derived MSCs ( UC-MSC ) also use treat severe autoimmune disease , therapy-resistant rheumatoid arthritis multiple sclerosis . The purpose study learn whether UC-MSC improve disease condition patient primary biliary cirrhosis . This study also look well UC-MSC tolerate safety PBC patient Participants study randomly assign one two treatment arm : Arm A : Participants receive 12 week UC-MSC treatment plus UDCA . Arm B : Participants receive 12 week placebo plus UDCA . UC-MSC prepared accord standard procedure collect plastic bag contain anticoagulant . UC-MSCs give via i.v . sonography monitoring . After cell therapy , patient follow week 4,8,12,24,36 48 . The evaluation clinical parameter level serum alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) total bilirubin ( TB ) , prothrombin time ( PT ) , albumin ( ALB ) , prealbumin ( PA ) , detect time point . Mayo risk score , portal hypertension , Liver histology , MELD score clinical symptom also observe simultaneously .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<criteria>1 . Written inform consent 2 . Primary Biliary Cirrhosis ( accord criterion define AASLD practice guideline , Hepatology , 2009 ; 50:291308 ) 3 . Negative pregnancy test ( female patient fertile age ) 1 . Hepatocellular carcinoma Malignancies 2 . Pregnant lactate woman 3 . Viral Hepatitis ( HAB , HBV , HCV , et al ) 4 . Vital organ failure ( Cardiac , Renal Respiratory , et al ) 5 . Sepsis 6 . Active thrombosis portal hepatic vein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Primary Biliary Cirrhosis</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Serum alkaline phosphatase</keyword>
	<keyword>Serum Bilirubin</keyword>
</DOC>